scispace - formally typeset
R

Russell B. McBride

Researcher at Icahn School of Medicine at Mount Sinai

Publications -  81
Citations -  4660

Russell B. McBride is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 30, co-authored 71 publications receiving 3677 citations. Previous affiliations of Russell B. McBride include Mount Sinai Hospital & Columbia University.

Papers
More filters
Journal ArticleDOI

Deep Learning to Improve Breast Cancer Detection on Screening Mammography

TL;DR: In this article, the authors developed an end-to-end deep learning algorithm that can accurately detect breast cancer on screening mammograms using an "end to end" training approach that efficiently leverages training datasets with either complete clinical annotation or only the cancer status (label) of the whole image.
Journal ArticleDOI

SARS-CoV-2 viral load predicts COVID-19 mortality.

TL;DR: In this paper, SARS-CoV-2 viral load at the time of presentation is an independent predictor of COVID-19 mortality in a large patient cohort (n=1,145).
Journal ArticleDOI

Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma

TL;DR: Among patients receiving chemotherapy for DLBCL, those with prior heart disease were less likely than others to be treated with doxorubicin, and those who received doxorbicin were more likely thanOthers to develop congestive heart failure (CHF).
Journal ArticleDOI

Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer

TL;DR: This study is the first to find that a substantial fraction of women with early-stage breast cancer terminated their chemotherapy prematurely and that early termination was associated with both black race and poorer survival.
Journal ArticleDOI

Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy

TL;DR: The use of G-CSF was associated with a doubling in the risk of subsequent AML or MDS among the population that was studied, although the absolute risk remained low.